Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

268.95 (USD) • At close November 12, 2024
Bedrijfsnaam Alnylam Pharmaceuticals, Inc.
Symbool ALNY
Munteenheid USD
Prijs 268.95
Beurswaarde 34,689,439,950
Dividendpercentage 0%
52-weken bereik 141.98 - 304.39
Industrie Biotechnology
Sector Healthcare
CEO Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB
Website https://www.alnylam.com

An error occurred while fetching data.

Over Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex

Vergelijkbare Aandelen

Insulet Corporation logo

Insulet Corporation

PODD

275.1 USD

BioMarin Pharmaceutical Inc. logo

BioMarin Pharmaceutical Inc.

BMRN

66.13 USD

Viatris Inc. logo

Viatris Inc.

VTRS

12.93 USD

Bio-Techne Corporation logo

Bio-Techne Corporation

TECH

74.41 USD

Incyte Corporation logo

Incyte Corporation

INCY

80.58 USD

ICON Public Limited Company logo

ICON Public Limited Company

ICLR

212.27 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)